[{"id":"59d4a003-e862-4682-ad7b-ffa3cb7e3e25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190174","created_at":"2021-01-18T15:43:45.733Z","updated_at":"2025-02-25T14:15:01.560Z","phase":"Phase 1/2","brief_title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","source_id_and_acronym":"NCT03190174","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2025-02-17"},{"id":"cd81acf1-3696-4c44-b81c-21f29e3189bd","acronym":"PRECISION 1","url":"https://clinicaltrials.gov/study/NCT05103358","created_at":"2021-11-02T17:57:05.457Z","updated_at":"2024-07-02T16:34:59.491Z","phase":"Phase 2","brief_title":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","source_id_and_acronym":"NCT05103358 - PRECISION 1","lead_sponsor":"Aadi Bioscience, Inc.","biomarkers":" TSC2 • TSC1","pipe":"","alterations":" ","tags":["TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/15/2022","start_date":" 02/15/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-03"},{"id":"71a6ad8e-f7a3-4f71-b131-a36389cfb2ab","acronym":"KRYSTAL -19","url":"https://clinicaltrials.gov/study/NCT05840510","created_at":"2023-05-03T15:04:42.504Z","updated_at":"2024-07-02T16:35:03.747Z","phase":"Phase 1/2","brief_title":"Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)","source_id_and_acronym":"NCT05840510 - KRYSTAL -19","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 08/07/2023","start_date":" 08/07/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-14"},{"id":"a5f51d8c-f1a9-41cc-b0e7-c7996b1fdc54","acronym":"","url":"https://clinicaltrials.gov/study/NCT03439462","created_at":"2023-11-24T19:34:17.807Z","updated_at":"2024-07-02T16:35:24.769Z","phase":"Phase 1/2","brief_title":"Nab-Sirolimus in Combination With FOLFOX \u0026 BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03439462","lead_sponsor":"Aadi Bioscience, Inc.","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 08/16/2022","primary_completion_date":" 08/16/2022","study_txt":" Completion: 08/26/2022","study_completion_date":" 08/26/2022","last_update_posted":"2024-01-01"},{"id":"aab204e3-bf39-4826-9848-4143e0d51a52","acronym":"","url":"https://clinicaltrials.gov/study/NCT02975882","created_at":"2021-01-18T14:37:49.288Z","updated_at":"2024-07-02T16:35:34.506Z","phase":"Phase 1","brief_title":"Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors","source_id_and_acronym":"NCT02975882","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 08/15/2017","start_date":" 08/15/2017","primary_txt":" Primary completion: 03/31/2022","primary_completion_date":" 03/31/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-10-06"},{"id":"f8417229-7488-4f2c-a0e3-2280e4a5e242","acronym":"","url":"https://clinicaltrials.gov/study/NCT02646319","created_at":"2021-01-18T12:52:33.455Z","updated_at":"2024-07-02T16:36:59.056Z","phase":"Phase 1","brief_title":"Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations","source_id_and_acronym":"NCT02646319","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • PIK3CA • STK11 • AKT1 • TSC2 • RHEB","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2 • PIK3CA • STK11 • AKT1 • TSC2 • RHEB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 09/05/2017","primary_completion_date":" 09/05/2017","study_txt":" Completion: 04/24/2018","study_completion_date":" 04/24/2018","last_update_posted":"2019-06-06"}]